


[Fig. 1]


Mesenteric lymph node
Inguinal lymph node
Spleen
IL-17A+ cells in CD4+ T cells (%)
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Solvent control group
Test substance administration group


[Fig. 2]



CD4-positive T cell
CD4-negative CD8-negative T cell
TCRβ chain-negative T cell
IL-17A+ cells in CD4+ T cells (%)
IL-17A+ cells in CD4-CD8- T cells (%)
IL-17A+ cells in TCRβ- cells (%)
1.4
1.2
1
0.8
0.6
0.4
0.2
0
3.5
3
2.5
2
1.5
1
0.5
0
90
80
70
60
50
40
30
20
10
0
Untreated group
Solvent control group
Test substance administration group

[Fig. 3]



IL-17A
Fold change
14
12
10
8
6
4
2
0
Untreated group
Solvent control group
Test substance administration group

[Fig. 4]


Time course change of auricle thickness
Auricle thickness (mm)
1
0.8
0.6
0.4
0.2
0
Untreated group
Solvent control group
Test substance administration group
0
7
14
21
28
35
42
Elapsed days after imiquimod-application


Auricle thickness on the 42nd day after imiquimod-application
Auricle thickness (mm)
1
0.8
0.6
0.4
0.2
0
Untreated group
Solvent control group
Test substance administration group

[Fig. 5]


IL-17A gene expression in auricle
Fold change
7000
6000
5000
4000
3000
2000
1000
0
Untreated group
Solvent control group
Test substance administration group